CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2014
Revenues:
Clinical laboratory services	$ 70,915	$ 63,414	$ 58,689
Product revenues	30,337	31,690	32,850
Royalty and license fee income	1,521	2,495	4,408
Total revenues	102,773	97,599	95,947
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services	42,859	39,589	38,948
Cost of product revenues	14,331	15,183	15,320
Research and development	3,524	3,350	3,141
Selling, general, and administrative	43,586	41,069	41,801
Provision for uncollectible accounts receivable	2,336	2,284	3,063
Legal fee expense	6,384	8,788	6,954
Legal settlements, net	(57,250)	(11,458)	(3,100)
Total costs, expenses and legal settlements, net	55,770	98,805	106,127
Operating income (loss)	47,003	(1,206)	(10,180)
Other income (expense):
Interest	(136)	(245)	(208)
Other	122	95	194
Foreign exchange (loss) gain	(474)	(936)	289
Income (loss) before income taxes	46,515	(2,292)	(9,905)
Benefit (provision) for income taxes	(1,229)	7	(72)
Net income (loss)	$ 45,286	$ (2,285)	$ (9,977)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.98	$ (0.05)	$ (0.23)
Diluted (in Dollars per share)	$ 0.97	$ (0.05)	$ (0.23)
Weighted average common shares outstanding:
Basic (in Shares)	46,153	45,355	42,561
Diluted (in Shares)	46,602	45,355	42,561